Company Profile

Nephros Inc
Profile last edited on: 6/9/2024      CAGE: -----      UEI: ----------

Business Identifier: Water purification products and pathogen detection systems for medical and commercial markets
Year Founded
1997
First Award
2003
Latest Award
2003
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

380 Lackawanna Place
South Orange, NJ 07079
   (201) 343-5202
   info@nephros.com
   www.nephros.com
Location: Multiple
Congr. District: 11
County: Bergen

Public Profile

Only briefly SBIR Involved and that some considerable time ago, with close ties to Columbia University Medical School. Nephros, Inc. (formerly OTC:NEPH - now NASDAQ:NEPH) is a medical device company now engaged in developing and selling water purification products and pathogen detection systems for the medical and commercial markets. A commercial-stage company developing and selling high-performance water purification products to the medical device and commercial markets, the company ultrafilters used in hospitals and medical clinics for added protection in retaining bacteria (e.g., Legionella, Pseudomonas) and viruses from water, providing barriers that assist in improving infection control in showers, sinks, and ice machines. Additionally, Nephros ultrafilters also used by dialysis centers for assisting in the added removal of endotoxins and other biological contaminants from the water and bicarbonate concentrate supplied to hemodialysis machines and patients

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : NEPH
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2003 1 NIH $99,837
Project Title: Improved Removal of Protein-Bound Toxins in Dialysis

Key People / Management

  John C Houghton -- Former President & CEO

  Paul A Mieyal -- Former Acting Chief Executive Officer

  Andy Astor -- CFO, COO

  Gregg Collins -- Vice President

  Gregory R Collins

  Daron Gxec Officer Pres And Di Evans -- Chief Exec. Officer, Pres and Director

  Mark Lerner -- Chief Financial Officer

  Wesley Lobo -- Chief Commercial Officer (CCO)

  Joleen C Turner -- VP of Marketing and VP of Bus. Devel.

Company News

There are no news available.